Pegylated interferon monotherapy for chronic hepatitis C

Seminars in Liver Disease

Volumn 24, Issue SUPPL. 2, 2004, Pages 39-45

  Heathcote, Jenny ^a   Zeuzem, Stefan ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Hepatitis C virus; Histology; Monotherapy; Pegylated interferon alfa 2a (40 kD); Pegylated interferon alfa 2b; Standard interferon; Viral kinetics; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; MACROGOL; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KINETICS; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MENTAL DISEASE; MONOTHERAPY; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VIRUS KINETICS; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 4444297900     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832927     Document Type: Review

References (18)

1. Barouki FM, Witter FR, Griffin DE, et al. Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987; 7:29-39
2. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-399
3. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv Drug Deliv Rev 1991;6:133-151
4. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 2004;24(suppl 2):33-38
5. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interfern alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000;32:647-653
6. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438
7. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672
8. Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
9. Zeuzem S, Herrmann E, Lee J-H, et al. Viral kinetics in patients with chronic hepatitis C treated with standard of peginterferon α2a. Gastroenterology 2001;120:1438-1447
10. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the anti-viral efficacy of interferon α therapy. Science 1998;282:103-107
11. Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-371
12. Ascione A, De Luca M, Canestrini C, et al. Efficacy of high dose of recombinant alfa 2b interferon on long term response in chronic hepatitis C and cirrhosis: perspective randomized multicentre study. Ital J Gastroenterol Hepatol 1998;30:517-523
13. Schalm SW, Weiland O, Hansen BE, et al. Interferon ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-413
14. Valla DC, Chevallier M, Marcelin P, et al. Treatment of hepatitis C virus related cirrhosis: a randomized, controlled trial of Interferon alfa-b versus no treatment. Hepatology 1999;29:1870-1875
15. Shiratori Y, Yokosuka O, Nakata R, et al. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:1573-1580
16. Lindsay K, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to Interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
17. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-936
18. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998;352:1426-1432